Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 7/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRK5 | P34947 | 1/20 | 0.33 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956342 | 0.86 | FYN (0.38) | CXCR2FYNBCL2BCL2L1GRK5 | |
| SCHEMBL956296 | 0.83 | CXCR2 (0.56) | CXCR2FYNBCL2BCL2L1GAA | |
| SCHEMBL956569 | 0.76 | ABCB1 (0.41) | — | |
| SCHEMBL957373 | 0.71 | CXCR2 (0.55) | CXCR2GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL3338299 | 0.70 | CXCR2 (0.52) | CXCR2FYN | |
| SCHEMBL3338709 | 0.64 | KDM1A (0.38) | CXCR2MAPK1SMN1; SMN2KDM1A | |
| SCHEMBL18770467 | 0.63 | BCL2 (0.41) | FYNBCL2BCL2L1HPGDSMN1; SMN2 | |
| SCHEMBL5286289 | 0.63 | TAAR1 (0.58) | HPGDSMN1; SMN2TAAR1 | |
| SCHEMBL30364680 | 0.63 | TAAR1 (0.58) | HPGDSMN1; SMN2TAAR1 | |
| SCHEMBL7892524 | 0.63 | MAPT (0.49) | FYNGAAHPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885FYN 337/4885BCL2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.